文献速递治疗药物监测与药物基因组学

儿童造血干细胞移植中静脉白消安的个体内药代动力学变异

Intra-individual Pharmacokinetic Variability of Intravenous Busulfan in Hematopoietic Stem Cell-Transplanted Children.
PubMed 文献 · Clin Pharmacokinet · 2020-01-01

该研究基于已发表数据重新分析136例接受4天静脉白消安预处理的患儿,发现多数患儿第1至第2天白消安清除率下降,中位变化-7.9%,但个体间波动大(最低-48.5%,最高+44%)。非线性混合效应模型显示清除率和分布容积的个体内变异系数分别为13.1%和10.6%,且变异难以预测,提示需反复进行治疗药物监测以实现精准给药。

要点

  • 儿童静脉白消安存在显著个体内药代动力学变异,清除率变化难以预测。
  • 第1至第3天平均清除率下降15%,22%患儿下降≥20%。
  • 反复进行治疗药物监测是准确评估暴露和精准给药的最佳方式。

核心结论

  • 儿童HSCT前静脉白消安存在显著的个体内药代动力学变异,且难以预测,主要风险为白消安过度暴露。
  • 反复进行治疗药物监测是准确估计白消安暴露并进行精准给药的最佳方式。

研究设计与样本

  • 对已发表数据的重新分析,纳入136例接受静脉白消安4天预处理后行HSCT的儿童。
  • 利用已发表的白消安群体药代动力学模型计算每日个体药代动力学参数并分析变化。
  • 采用非线性混合效应模型估计个体内变异,并用机器学习方法评估清除率显著下降的预测因素。

主要发现

  • 第1至第2天,80%患儿白消安清除率下降,中位变化-7.9%,但变化范围大(最低-48.5%,最高+44%)。
  • 第1至第3天,平均清除率显著下降15%,22%患儿下降≥20%。
  • 部分患儿清除率逐日不稳定。
  • NLME模型估计分布容积和清除率的个体内变异系数分别为10.6%和13.1%。
  • 虽识别出清除率显著下降的一些决定因素,但模型预测性能有限。

临床怎么用

  • 儿童静脉白消安治疗期间应反复进行治疗药物监测,以准确估计暴露并实施精准给药。
  • 需警惕白消安清除率下降导致的过度暴露风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Busulfan therapeutic drug monitoring (TDM) is necessary to better achieve the target exposure in children before hematopoietic stem cell transplantation (HSCT). However, TDM-based dosing may be challenging if intra-individual pharmacokinetic variability (also denoted inter-occasion variability [IOV]) occurs during therapy. OBJECTIVES: The objectives of this study were to describe and quantify busulfan IOV in children, and to investigate its potential determinants. METHODS: We performed a new analysis of published data from children who received intravenous busulfan over 4 days before HSCT. We calculated individual pharmacokinetic parameters on each day of therapy using a published population pharmacokinetic model of busulfan and analyzed their changes. Population estimation of IOV was also performed with non-linear mixed effects (NLME) modeling. Potential predictors of significant decrease in busulfan clearance (CL) were assessed by using machine learning approaches. RESULTS: IOV could be assessed in 136 children. Between day (D) 1 and D2, most patients (80%) experienced a decrease in busulfan CL, with a median change of - 7.9%. However, both large decreases (minimum, - 48.5%) and increases in CL (maximum, + 44%) were observed. Over D1-D3 of therapy, mean CL significantly decreased (- 15%), with a decrease of ≥ 20% in 22% of patients. Some patients also showed unstable CL from day to day. NLME modeling of IOV provided a coefficient of variation of 10.6% and 13.1% for volume of distribution (Vd) and CL, respectively. Some determinants of significant decreases in busulfan CL were identified, but predictive performance of the models was limited. CONCLUSIONS: Significant busulfan intra-individual variability may occur in children who receive a HSCT and is hardly predictable. The main risk is busulfan overexposure. Performing TDM repeatedly over therapy appears to be the best way to accurately estimate busulfan exposure and perform precision dosing.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Marsit H, Philippe M, Neely M, et al. Intra-individual Pharmacokinetic Variability of Intravenous Busulfan in Hematopoietic Stem Cell-Transplanted Children. Clin Pharmacokinet. 2020. PMID: 32157629. doi:10.1007/s40262-020-00877-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。